Provided by Tiger Fintech (Singapore) Pte. Ltd.

Precision Biosciences Inc

5.36
+0.03000.56%
Volume:8.21K
Turnover:42.98K
Market Cap:56.18M
PE:5.15
High:5.36
Open:5.28
Low:5.18
Close:5.33
Loading ...

Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for Pbgene-Hbv for Treatment of Chronic Hepatitis B

THOMSON REUTERS
·
15 Nov 2024

Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis B

Business Wire
·
15 Nov 2024

Precision BioSciences Inc reports results for the quarter ended in September 30 - Earnings Summary

Reuters
·
04 Nov 2024

BRIEF-Precision BioSciences Reports Q3 Financial Results And Provides Business Update

Reuters
·
04 Nov 2024

Precision BioSciences (DTIL) Reports Q3 Loss, Misses Revenue Estimates

Zacks
·
04 Nov 2024

Precision BioSciences Shares Down 3.6% Premarket After Q3 Results

THOMSON REUTERS
·
04 Nov 2024

Precision BioSciences: Q3 Earnings Snapshot

Associated Press Finance
·
04 Nov 2024

Precision BioSciences Q3 2024 GAAP EPS $(2.25), Inline, Sales $576.000K Miss $6.356M Estimate

Benzinga
·
04 Nov 2024

Precision BioSciences Inc: Expected Cash Runway Into Second Half of 2026

THOMSON REUTERS
·
04 Nov 2024

Precision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update

THOMSON REUTERS
·
04 Nov 2024

Precision BioSciences, Inc. Q3 Net Income USD -16.425 Million

THOMSON REUTERS
·
04 Nov 2024

Precision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update

Business Wire
·
04 Nov 2024

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
04 Nov 2024

Precision BioSciences Inc expected to post a loss of $1.92 a share - Earnings Preview

Reuters
·
01 Nov 2024

Precision BioSciences (DTIL) Surges 6.1%: Is This an Indication of Further Gains?

Zacks
·
01 Nov 2024

Press Release: Precision BioSciences to Report Third Quarter Results on November 4, 2024

Dow Jones
·
29 Oct 2024

Precision BioSciences to Host Virtual Investor Event Highlighting PBGENE-HBV Preclinical Safety Data and Phase 1 Clinical Trial Plans on November 15, 2024

Business Wire
·
28 Oct 2024